Clavix Tablets (Clopidogrel Hydrochloride)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this drug once daily on the day treatment is initiated, followed by an oral maintenance dose of 75 mg once daily. Aspirin 75 ～ 325 mg should be administered concomitantly with this drug once daily. 3. For patients with atrial fibrillation, administer 75 mg of this drug orally once daily. Aspirin 75 ～ 100 mg should be administered concomitantly with this drug once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate liver disease and a bleeding diathesis is limited. This drug may be administered with or without food.

This medication helps prevent platelets from clumping together, thereby aiding in blood flow. It may be less effective in individuals with a genetic deficiency of a specific enzyme (CYP2C19), in which case alternative treatment should be considered. Additionally, co-administering this medication with drugs that activate specific enzymes may increase the risk of bleeding, so it is advised not to use them together. This medication should not be used in patients with bleeding disorders, severely impaired liver function, breastfeeding women, or those with certain genetic disorders such as lactose intolerance. Patients at high risk of bleeding or scheduled for surgery should use this medication cautiously, and may need to discontinue it a certain period before surgery. If bleeding symptoms occur during treatment with this medication, the physician should be consulted immediately. This medication may interact with various other drugs, especially when taken with those that increase bleeding risk, thus caution is required. During pregnancy, the effects on the fetus should be considered, and it should be used only when necessary; in breastfeeding cases, careful consideration should be given to whether to continue breastfeeding while taking this medication. The safety and efficacy for children have not yet been adequately established. Elderly patients or those with decreased kidney function may be at higher risk for bleeding, and dosage adjustments and caution are necessary. In cases of overdose, the risk of bleeding may increase, and as there is no specific antidote, treatments such as platelet transfusions may be necessary in cases of severe bleeding. This medication should be stored out of reach of children and not transferred to other containers. During treatment, it may take longer for bleeding to stop, so if bleeding persists or abnormal symptoms occur, medical personnel should be informed immediately.

Hemorrhage, gastrointestinal bleeding, required hospitalization for bleeding, purpura, contusion, hematoma, epistaxis, hematoma, hematuria, intraocular hemorrhage, intracranial hemorrhage, major hemorrhage, minor hemorrhage, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, abdominal pain, dyspepsia, diarrhea, nausea, rash, pruritus, urinary tract infection, chest pain, accidental injury, influenza-like illness, pain, fatigue, edema, hypertension, headache, dizziness, depression, shortness of breath, rhinitis, bronchitis, cough, urinary tract infection, decreased motor function, tremor, voice disorder, abnormal gait, hyperkinesia, ataxia, sensory disturbances, constipation, vomiting, ulcer, abdominal pain, decreased appetite, hiccups, thirst, dysphagia, tongue disorders, insomnia, depression, amnesia, anxiety, confusion, abnormal behavior, joint pain, myalgia, back pain, arthrosis, weight loss, weight gain, facial flushing, weakness, rigidity, facial edema, syncope, purpura, hematochezia, thrombocytopenia, anemia, pneumonia, sinusitis, visual disturbances, visual field defects, dry eyes, transient blindness, congestion, tinnitus, taste disorder, urinary disorders, polyuria, non-protein nitrogen increase, uremia, increased blood urea nitrogen, hypoglycemia, hyperuricemia, increased liver enzymes, elevated ALT, liver dysfunction, leg edema, arrhythmia, bradycardia, palpitations, contact dermatitis, gynecomastia, elevated prostate-specific antigen, allergic symptoms, ischemic necrosis, gastritis, hemorrhagic gastroenteritis, duodenal ulcer, gastric ulcer, perforated gastric ulcer, upper gastrointestinal tract ulcer hemorrhage, distension, bilirubinemia, infectious hepatitis, fatty liver, hemorrhagic arthropathy, hematuria, hemoptysis, intracranial hemorrhage, retroperitoneal hemorrhage, ocular hemorrhage, pulmonary hemorrhage, thrombocytopenia, anemia, aplastic anemia, hypochromic anemia, agranulocytosis, granulocytopenia, leukemia, leukopenia, neutropenia, eosinophilia, menorrhagia, hemothorax, major herpes, erythematous rash, maculopapular rash, urticaria, renal dysfunction, acute renal failure, cholecystitis, hematemesis, spinal hematoma

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to keep it at room temperature between 1 to 30 degrees Celsius, away from extreme heat or cold.

Appearance

Pink round film-coated tablets

Package unit

Domestic use - 30 tablets/bottle, Domestic use - 100 tablets/bottle, Export use - 30 tablets/box [(10 tablets/PTP*3)]